Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …

Liver metastases are commonly detected in a range of malignancies including colorectal
cancer (CRC), pancreatic cancer, melanoma, lung cancer and breast cancer, although CRC …

Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …

Monoclonal antibody-based immunotherapy is now considered to be a main component of
cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies …

Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …

KRAS is the most frequently mutated oncogene, harboring mutations in approximately one
in seven cancers. Allele-specific KRASG12C inhibitors are currently changing the treatment …

Reactive oxygen species (ROS) constitute a group of highly reactive molecules that have
evolved as regulators of important signaling pathways. It is now well accepted that moderate …

Abstract Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …